The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db/Db mice by suppressing the expression of foxo1

Takuro Okamura,1 Yoshitaka Hashimoto,1 Takafumi Osaka,1,2 Takeya Fukuda,1 Masahide Hamaguchi1 and Michiaki Fukui1,*

1Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan
2Department of Diabetology, Ayabe City Hospital, Ayabe 623-0011, Japan

(Received 27 December, 2018; Accepted 20 January, 2019; Published online 18 May, 2019)

We investigated the effect of the sodium glucose cotransporter-2 inhibitor (SGLT-2i) luseogliflozin on skeletal muscle. Eight-week-old mice were fed a standard diet or the standard diet with added luseogliflozin for 8 weeks. The mice were divided into the following four genotype/dietary groups: Db/m mice without SGLT-2i, Db/m mice with SGLT-2i inhibitor, Db/Db without SGLT-2i, and Db/Db with SGLT-2i. Among the mice with and without SGLT-2i, the ratio of soleus and plantaris muscle to body weight in the Db/Db mice was significantly lower than that in the Db/m mice. The cross-sectional area of soleus muscle in the Db/Db mice without SGLT-2i was significantly higher than that in the Db/Db mice with SGLT-2i. The expression of foxo1 in soleus muscle of the Db/Db mice was significantly higher than that of the Db/m mice, and the foxo1 expression of the Db/Db mice with SGLT-2i was significantly lower than that of the mice without SGLT-2i. The fluorescence intensity of foxo1 in the Db/Db mice fed SGLT-2i was significantly lower than that in the Db/Db mice without SGLT-2i. The administration of luseogliflozin resulted in the suppression of both the increased foxo1 expression and the reduced muscle cross-sectional area in the soleus muscle of Db/Db mice.

Key Words: sodium glucose cotransporter-2 inhibitor, luseogliflozin, muscle atrophy, foxo1, sarcopenia

The numbers of individuals with type 2 diabetes are rapidly increasing worldwide. Complications of type 2 diabetes reduce a person’s quality of life, and they add a heavy burden to the medical economy.1 The prevention of the progression of diabetic complications is thus an important task. In recent years, muscle atrophy has been thought of as a complication of diabetes.2 It has become clear that muscle atrophy, i.e., sarcopenia, and sarcopenic obesity are strongly associated with dietary pattern or metabolic disorder.3,4 In fact, we demonstrated that muscle atrophy is present in diabetic patients.5,6 Muscle atrophy is also a risk factor for both decreased daily life activity and mortality.7,8

Several sodium glucose cotransporter-2 inhibitors (SGLT2i) have recently become available as anti-diabetic medications, and some of them have been reported to reduce the risk of incident cardiovascular disease.9,10 The effects of SGLT2i on body composition have been described,11,12 but the mechanisms underlying these effects on muscle have been unclear. We conducted the present study to investigate the effects of the SGLT2i luseogliflozin on muscle in Db/Db mice. We evaluated muscle atrophy using cross-sectional areas of muscle because this method has been often used as the best objective indicator of muscle atrophy.13,14 We also evaluated the changes in gene expression in skeletal muscle following the administration of SGLT2i. The genes mstn, pgc1a, and foxo1 are related to muscle atrophy.15–17 We focused on foxo1 in this study because the foxo1 expression of skeletal muscle in individuals with diabetes is accelerated, and this suppresses the glucose utilization and lipid synthesis in skeletal muscle.18–20

Materials and Methods

Animals and experimental design. All experimental procedures were approved by the Committee for Animal Research, Kyoto Prefectural University of Medicine. Six-week-old male non-diabetic heterozygous Db/m mice and 6-week-old male diabetic homozygous Db/Db mice were purchased from Shimizu Laboratory Supplies (Kyoto, Japan). Starting when the mice were 8 weeks old, they were fed either a standard diet (SD; 344.9 kcal/100 g, fat kcal 4.6%; CLEA Japan, Tokyo, Japan) or the same standard diet with the SGLT2i luseogliflozin added (0.01% w/w in chow) for 8 weeks. We divided the mice into the following four groups: (1) Db/m without (w/o) SGLT2i, (2) Db/m with SGLT2i, (3) Db/Db w/o SGLT2i, and (4) Db/Db with SGLT2i. At 16 weeks old, after an overnight fast, all of the mice were killed by the administration of a combination anesthetic: 0.3 mg/kg of medetomidine, 4.0 mg/kg of midazolam, and 5.0 mg/kg of butorphanol (Fig. 1A).21

Glucose tolerance tests. Intraperitoneal glucose tolerance tests (iPGTTs) (2 g/kg) were performed in other 16-week-old mice that had been fasted for 5 h. Plasma glucose was measured from the tail vein using a glucometer (Gultest Neo Alpha; Sanwa Kagaku Kenkyusho, Nagoya, Japan).

Tissue collection and histological assessment of murine soleus and plantaris muscles. We used the soleus and plantaris muscles for the muscle samples.22 The soleus muscle was either fixed with 10% buffered formaldehyde for the histological examination or immediately frozen in QIAzol Lysis reagent (Qiagen, Venlo, Netherlands) for mRNA extraction. We measured the weight and cross-sectional area of soleus and plantaris muscles of the four groups of mice described above. In this study, we used the anatomical cross-sectional area, which is the cross-sectional...
area of a muscle perpendicular to its longitudinal axis of soleus muscle.\(^{(22)}\)

Soleus muscle sections were prepared and stained with hematoxylin and eosin or a monoclonal \textit{foxo1} (C29H4) antibody (Cell Signaling Technology, Beverly, MA) as a primary antibody, and a Texas-red-conjugated anti-mouse secondary antibody (Jackson ImmunoResearch, West Grove, PA). Nuclei were stained with DAPI (Sigma-Aldrich, St. Louis, MO). Images were captured with a fluorescence microscope (BZ-X710, Keyence, Osaka, Japan), and the fluorescence intensity of the muscle tissue and the cell nuclei numbers were analyzed using Image J software. We measured the weights of the soleus and plantaris muscles and the cross-sectional areas of soleus muscle of the mice in the four groups described above. All images acquired using the BZ-X710 microscope and the cross-sectional areas of soleus muscle were measured using BZ-X analyzer software (Keyence).

**Gene expression in soleus muscle.** The soleus muscle of fasting mice were resected and immediately frozen using liquid nitrogen and homogenized in ice-cold QIAzol Lysis reagent, and total RNA was isolated as described in the manufacturer’s instructions. We reverse-transcribed the total RNA (0.5 \(\mu\)g) by using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) for first-strand cDNA synthesis utilizing an oligonucleotide dT primer and random hexamer priming according to the manufacturer’s recommendations. The reverse transcription (RT) reaction was performed for 120 min at 37 °C, and the inactivation of RT was performed for 5 min at 85°C.

The mRNA expression levels of \textit{foxo1}, \textit{myog}, \textit{mstn}, \textit{myod}, \textit{pgc1a} and \textit{ppara} were quantified using a real-time reverse transcription-polymerase chain reaction (RT-PCR). The relative expression levels of each targeted gene was normalized to the \textit{gapdh} threshold cycle (CT) values and quantified using the comparative threshold cycle 2\(^{-\Delta\Delta CT}\) method as described.\(^{(22)}\) Signals from Db/m mice without SGLT2i feeding were assigned a relative value of 1.0. The RT-PCR was performed using TaqMan Fast Advanced Master Mix (Applied Biosystems) according to the manufacturer’s instructions. The following PCR conditions were used: 1 cycle for 2 min at 50°C and 20 s at 95°C, followed by 40 cycles for 1 s at 95°C, and 10 s at 60°C.

**Statistical analysis.** We analyzed the data using the JMP ver. 13.0 software (SAS, Cary, NC), and \(p\) values <0.05 were considered significant. Student’s \(t\) test was used to compare the differences between pairs of groups.

**Results**

**Effect of SGLT-2i on body weight and glucose homeostasis**

After the 8-week dietary treatment, the body weight and blood glucose in the two groups of Db/Db mice (those with and w/o the SGLT2i) were significantly higher than those of the two groups of Db/m mice. However, no significant reduction in body weight and no improvement in impaired glucose tolerance were observed following the administration of SGLT-2i (Fig.1B–D).

**Effect of SGLT-2i on skeletal muscle.** In the mice treated with and without SGLT-2i, the weight of the soleus muscle of the Db/Db mice was significantly lower than that in the Db/m mice, whereas the weight of the plantaris muscle did not show a significant difference between the Db/Db and Db/m mice (Fig. 2A and B). Additionally, among the mice treated with and without SGLT-2i, the plantaris and soleus muscle to body weight ratio in the Db/Db mice was significantly lower than that in the Db/m mice (Fig. 2C and D). The cross-sectional area of soleus muscle in the Db/Db mice without SGLT-2i was significantly less than that in the Db/Db mice with SGLT-2i (Fig. 3A–E).

**SGLT-2i suppressed foxo1 expression in muscle.** Our RT-PCR analyses revealed that the \textit{foxo1} expression in skeletal muscle of the Db/Db mice was significantly higher than that of the Db/m mice (Fig. 4A). However, the \textit{foxo1} expression in skeletal muscle of the Db/Db mice with SGLT-2i was significantly lower than that in the mice without SGLT-2i (Fig. 4A).
Fig. 2. Luseogliflozin in the diet did not change the muscle weights of the mice. (A) Plantaris muscle weights (n = 6). (B) Soleus muscle weights (n = 6). (C) Ratio of plantaris muscle to body weight (n = 6). (D) Ratio of soleus muscle to body weight (n = 6). Data are mean ± SEM. *p<0.05, **p<0.01 by t test.

Fig. 3. Histological assessment of the soleus muscle. Luseogliflozin increased the cross-sectional area of soleus muscle. (A–D) Cross-sections of soleus muscle. (A) Db/m without SGLT2i. (B) Db/m with SGLT2i. (C) Db/Db without SGLT2i. (D) Db/Db with SGLT2i. Scale bar, 200 μm. (E) Cross-sectional area of soleus muscle. Data are mean ± SEM. *p<0.01 by t test.
istration of SGLT-2i did not change the expressions of any other genes in the Db/m and Db/Db mice (Fig. 4B–F). In addition, the immunostaining of soleus muscle tissues demonstrated that the fluorescence intensity of \( \text{foxo1} \) in the Db/Db w/o SGLT2i group was significantly higher than that of the Db/Db with SGLT2i group (Fig. 5A–E). Moreover, the number of cell nuclei per image in both the Db/m mice and the Db/Db mice treated with SGLT-2i were higher than those of the mice w/o SGLT-2i (Fig. 5F).

**Discussion**

Our findings demonstrated that the \( \text{foxo1} \) expression in skeletal muscle of Db/Db mice is higher than that of Db/m mice and that an SGLT2i, luseogliflozin, suppressed this higher \( \text{foxo1} \) expression in skeletal muscle of Db/Db mice. Increased \( \text{foxo1} \) expression in skeletal muscle was reported to be associated with muscle atrophy.\(^{(24, 25)}\) \( \text{Foxo1} \) could affect several metabolic pathways. Among them, proteolysis regulated by the ubiquitin-proteasome pathway, autophagy, and the repression of protein synthesis are dominant processes of muscle atrophy.\(^{(17, 26)}\)

In addition, \( \text{foxo1} \) has been thought to have a pivotal role in glycolysis in muscle. In fact, increased \( \text{foxo1} \) expression resulted in the upregulation of \( \text{pdk4} \) expression, which suppresses the glycolytic pathway.\(^{(18)}\) Increased \( \text{foxo1} \) expression represses the expression of \( \text{srebp1c} \), which is mediated by nuclear receptors (such as liver X receptor and retinoid X receptor), and it upregulates the biosynthesis of fatty acid in skeletal muscle.\(^{(19)}\) Therefore, increased \( \text{foxo1} \) expression in skeletal muscle suppresses glucose utilization and lipid synthesis.

In the present study, the ratio of plantaris and soleus muscle to body weight in the Db/Db mice were significantly lower than that in the Db/m mice. Moreover, the cross-sectional area of soleus muscle in the Db/Db mice treated with SGLT2i was significantly higher than that of the mice w/o SGLT2i.

This study has some limitations. First, the sample size was small. Second, we did not investigate the biological mechanism of luseogliflozin in vitro. This issue is very important and should be addressed in future studies.

**Conclusion**

Taken together, our present findings suggest that increased \( \text{foxo1} \) expression in skeletal muscle is associated with the muscle atrophy of Db/Db mice. This is the first study to demonstrate the increased expression of \( \text{foxo1} \) in muscle tissue of Db/Db mice. The administration of luseogliflozin resulted in the suppression of both the increased \( \text{foxo1} \) expression and the reduced muscle cross-sectional area in the soleus muscle of Db/Db mice. Further studies investigating the association between the effect of an SGLT-2i on muscle and \( \text{foxo1} \) in muscle are needed.

**Acknowledgments**

We thank all of the staff members of the Kyoto Prefectural University of Medicine. This research received funding from Taishi Toyama Pharmaceutical Co., Ltd.
Abbreviations

iPGTT intraperitoneal glucose tolerance tests  
RT reverse transcription  
RT-PCR real-time reverse transcription-polymerase chain reaction  
SD standard diet  
SGLT-2i sodium glucose cotransporter-2 inhibitor  
w/o without  

Conflict of Interest

Y. Hashimoto received grants from the Fuji Foundation for Protein Research, outside the submitted work. M. Fukui reports grants from AstraZeneca, grants from Astellas Pharma, grants from Nippon Boehringer Ingelheim, grants from Daiichi Sankyo Co., grants from Eli Lilly Japan, grants from Kyowa Hakko Kirin Co., grants from Kissei Pharmaceutical Co., grants from MSD, grants from Mitsubishi Tanabe Pharma Corp., grants from Novo Nordisk Pharma, grants from Sanwa Kagaku Kenkyusho Co., grants from Sanofi, grants from Ono Pharmaceutical Co., and grants from Takeda Pharmaceutical Co., outside the submitted work. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. The authors declare that although they are affiliated with a department that is supported financially by pharmaceutical company, the authors received no current funding for this study and this does not alter their adherence to all the journal policies on sharing data and materials. The other authors have nothing to disclose.
References

1. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol 2017; 14: 88–98.

2. Okamura T, Miki A, Hashimoto Y, et al. Shortage of energy intake rather than protein intake is associated with sarcopenia in elderly patients with type 2 diabetes: a cross-sectional study of the KAMOGAWA-DM cohort. J Diabetes 2018; DOI: 10.1111/1753-0407.12874.

3. Park S, Na W, Sohn C. Relationship between osteosarcopenic obesity and dietary inflammatory index in postmenopausal Korean women: 2009 to 2011 Korea National Health and Nutrition Examination Surveys. J Clin Biochem Nutr 2018; 63: 211–216.

4. Kim TN, Park MS, Yang SJ, et al. The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes. Endocr J 2016; 63: 877–884.

5. Osaka T, Hashimoto Y, Fukuda T, Tanaka M, Yamazaki M, Fukui M. Relationship between skeletal muscle mass and hepatic fibrosis in patients with type 2 diabetes. Diabetes Metab 2017; 43: 184–186.

6. Lim S, Kim JH, Yoon JW, et al. Sarcopenia obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetics Care 2010; 33: 1497–1499.

7. Hashimoto Y, Osaka T, Fukuda T, Tanaka M, Yamazaki M, Fukui M. Relationship between skeletal muscle mass and hepatic fibrosis in patients with type 2 diabetes. Diabetes Metab 2017; 43: 184–186.

8. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889–896.

9. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

10. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.

11. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014; 16: 159–169.

12. Yokono M, Takasu T, Hayashiizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014; 727: 66–74.

13. McPherron AC, Lawler AM, Lee S-J. Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature 1997; 387: 83–90.

14. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 1014–1019.

15. Ma K, Mallidis C, Bhasin S, et al. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Metab 2003; 285: E363–E371.

16. Sandri M, Lin J, Handschin C, et al. PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci U S A 2006; 103: 16260–16265.

17. Sandri M, Sandri C, Gilbert A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399–412.

18. Furuyama T, Kitayama K, Yamashita H, Mori N. Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation. Biochem J 2003; 375 (Pt 2): 365–371.

19. Kamei Y, Miura S, Suganami T, et al. Regulation of SREBP1c gene expression in skeletal muscle: Role of retinoid X receptor/liver X receptor and forkhead-O1 transcription factor. Endocrinology 2008; 149: 2293–2305.

20. Kawai S, Takagi Y, Kaneko S, Karasawa T. Effect of three types of mixed anesthetic agents alternate to ketamine in mice. Exp Anim 2011; 60: 481–487.

21. Carnwath JW, Shotton DM. Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. J Neurol Sci 1987; 80: 39–54.

22. Timson BF, Bowlin BK, Dudenhoeffer GA, George JB. Fiber number, area, and composition of mouse soleus muscle following enlargement. J Appl Physiol 1985; 58: 619–624.

23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2$^{-}$DD method. Methods 2001; 25: 402–408.

24. Léger B, Cartoni R, Praz M, et al. Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2006; 576 (Pt 3): 923–933.

25. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001; 98: 14440–14445.

26. Mammeuari C, Milan G, Romanello V, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458–471.